Life Sciences a ‘Top Priority’ for Agilent As Firm Considers M&A Options, CEO Says Bill Sullivan said Agilent remains on the lookout for acquisition targets, and that the firm’s “top priority continues to be in the life-sciences area, and we will continue to look for opportunities that we believe will drive value for shareholders.”
Move Beyond Setbacks and Just Do It, Researchers Tell AACC Attendees At last week’s American Association for Clinical Chemistry’s conference on translating proteomics from discoveries into diagnostics, presenters focused less on beating up on themselves for past setbacks and more on figuring out how to move past their shortcomings to create a genuine clinical pipeline.
![Publishing Systems Powered by iProduction [martha]](/images-genomeweb/small_iproduction_logo.gif "Publishing Systems Powered by iProduction [ martha]"){kind=logo}